DataSheet_1_The evaluation of JAK inhibitors on effect and safety in alopecia areata: a systematic review and meta-analysis of 2018 patients.docx

BackgroundJAK inhibitors treat various autoimmune diseases, but an updated systematic review in treating alopecia areata is currently lacking.
ObjectiveEvaluate the specific efficacy and safety of JAK inhibitors in alopecia areata by systematic review and meta-analysis.
MethodsEligible studies in PubMed, Embase, Web of Science, and Clinical Trials up to May 30, 2022, were searched. We enrolled in randomized controlled trials and observational studies of applying JAK inhibitors in alopecia areata.
Results6 randomized controlled trials with 1455 patients exhibited SALT50 (odd ratio [OR], 5.08; 95% confidence interval [CI], 3.49-7.38), SALT90 (OR, 7.40; 95% CI, 4.34-12.67) and change in SALT score (weighted mean difference [WSD], 5.55; 95% CI, 2.60-8.50) compared to the placebo. The proportion of 26 observational studies with 563 patients of SALT5 was 0.71(95% CI, 0.65-0.78), SALT50 was 0.54(95% CI 0.46-0.63), SALT90 was 0.33(95% CI, 0.24-0.42), and SALT score (WSD, -2.18; 95% CI, -3.12 to -1.23) compared with baseline. Any adverse effects occurred in 921 of 1508 patients; a total of 30 patients discontinued the trial owing to adverse reactions.
LimitationsFew randomized controlled trials met the inclusion criteria and insufficiency of eligible data.
ConclusionJAK inhibitors are effective in alopecia areata, although associated with an increased risk.

背景：JAK抑制剂（Janus Kinase Inhibitor）可用于治疗多种自身免疫性疾病，但目前尚缺乏针对斑秃（alopecia areata）治疗的最新系统评价。
目的：采用系统评价与Meta分析（Meta-analysis）的方法，评估JAK抑制剂治疗斑秃的具体疗效与安全性。
方法：检索截至2022年5月30日PubMed、Embase、Web of Science及Clinical Trials数据库中符合纳入标准的相关研究；纳入JAK抑制剂治疗斑秃的随机对照试验与观察性研究。
结果：纳入1455例患者的6项随机对照试验显示，与安慰剂组相比，JAK抑制剂治疗后患者的SALT50达标率（比值比[Odds Ratio, OR]=5.08，95%置信区间[Confidence Interval, CI]=3.49~7.38）、SALT90达标率（OR=7.40，95%CI=4.34~12.67）及SALT评分变化值（加权均数差[Weighted Mean Difference, WMD]=5.55，95%CI=2.60~8.50）均存在显著统计学差异。纳入563例患者的26项观察性研究显示，与基线相比，患者的SALT5达标率为0.71（95%CI=0.65~0.78），SALT50达标率为0.54（95%CI=0.46~0.63），SALT90达标率为0.33（95%CI=0.24~0.42），SALT评分加权均数差为-2.18（95%CI=-3.12~-1.23）。1508例患者中共有921例出现任意类型不良反应，共计30例患者因不良反应终止试验。
局限性：符合纳入标准的随机对照试验数量较少，且可用合格数据存在不足。
结论：JAK抑制剂治疗斑秃具有明确疗效，但会增加不良反应发生风险。